Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Dagny Holle-Lee, MD, PhD, Essen University Hospital, Essen, Germany, discusses the results of three randomized, double-blind, placebo-controlled Phase III studies evaluating the early efficacy of galcanezumab in older patients with migraine. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.